[go: up one dir, main page]

EP1061988A1 - Procedes d'embolotherapie gynecologique endovasculaire - Google Patents

Procedes d'embolotherapie gynecologique endovasculaire

Info

Publication number
EP1061988A1
EP1061988A1 EP99908568A EP99908568A EP1061988A1 EP 1061988 A1 EP1061988 A1 EP 1061988A1 EP 99908568 A EP99908568 A EP 99908568A EP 99908568 A EP99908568 A EP 99908568A EP 1061988 A1 EP1061988 A1 EP 1061988A1
Authority
EP
European Patent Office
Prior art keywords
contrast agent
biocompatible
composition
polymer
tantalum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99908568A
Other languages
German (de)
English (en)
Inventor
Richard J. Greff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micro Therapeutics Inc
Original Assignee
Micro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Therapeutics Inc filed Critical Micro Therapeutics Inc
Publication of EP1061988A1 publication Critical patent/EP1061988A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18—Materials at least partially X-ray or laser opaque
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B2017/4216—Operations on uterus, e.g. endometrium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3933—Liquid markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Definitions

  • This invention is directed to novel methods for gynecologic embolotherapy by endovascular embolization with a fluid embolic composition which in situ in the blood vessel forms a coherent solid mass.
  • the methods provide precise directed delivery of embolic fluid compositions and are particularly suited for treating uterine fibroids.
  • the fluid embolic compositions comprise a biocompatible polymer, a biocompatible solvent and a biocompatible water insoluble contrast agent.
  • the contrast agent is characterized by having an average particle size of about 10 ⁇ m or less.
  • Vedantham, et al. "Uterine artery embolization: An underused method of controlling pelvic hemorrhage," Am. J. Obstet. Gynecol. 176(4):938-948 (1997)
  • Gynecologic embolotherapy may be conducted for a variety of purposes including the treatment of postpartum and postcaesarean bleeding, the treatment of postsurgical vaginal bleeding, the prevention and/or treatment of hemorrhage from ectopic pregnancy, prophylactically prior to myomectomy and in obstetrical patients at high risk for bleeding, such as those patients with placenta previa, placenta accreta, uterine fibroids and twin fetal death.
  • Gynecological embolotherapy has only been used for non-malignant conditions and the literature reports the use of poly vinyl alcohol (PVA) particles of sizes varying from 150 to 700 ⁇ m as the embolizing agents. 16
  • Complications arising from endovascular embolization using PVA particles include complications of angiography, pelvic infection, pelvic pain and ischemia.
  • the incidence of postembolization pelvic pain has been attributed to the size of the PVA particles employed with smaller particles associated with higher incidences of pelvic pain.
  • such small particles are not visualible under fluoroscopy and, accoridngly, can migrate during injection causing unwanted ischemia and necrosis. 17 Small particles such as PVA can also compact and migrate resulting in incomplete embolization and recanalization. l0
  • uterine fibroid shrinkage was noted in patients with fibroids following gynecological embolization of these patients for acute bleeding, leading to the establishment of several clinical programs which use uterine artery embolization for the treatment of uterine fibroids.
  • Clinical success of uterine artery embolization (defined as improvement in bleeding, pain and mass effect such that no further operative therapy is required) is good.
  • Fibroid size is reduced, on average, by about 50% in patients undergoing uterine artery embolization. 16,17
  • gynecological embolization methods for treatment and/or prevention of gynecological and/or obstetrical bleeding disorders which provide for delivery of substantially fluid compositions (e.g. , compositions comprising particles having maximum average particle size of less than 100 ⁇ m) to be delivered to the uterine artery would be beneficial as these compositions.
  • substantially fluid compositions e.g. , compositions comprising particles having maximum average particle size of less than 100 ⁇ m
  • compositions preferably comprise a biocompatible solvent, a biocompatible polymer and a contrast agent which is preferably a water insoluble contrast agent of less than 100 ⁇ m in average particle size and more preferably less than 10 ⁇ m in average particle size.
  • embolization compositions have been employed in vascular embolization for treating aneurysms, tumors, arteriovenous - 5 --
  • the use of water insoluble, radiopaque contrast agent in these compositions permits the physician to visualize delivery of the composition to the vascular site via conventional techniques such as fluoroscopy.
  • the use of water insoluble contrast agents is beneficial during posttreatment procedures to visualize the embolized mass during, for example, surgery or to monitor the disease condition and/or for retreatment purposes. Visualization is particularly necessary when using catheter delivery techniques in order to ensure both that the composition is being delivered to the intended vascular site and that the requisite amount of composition is delivered.
  • the water insoluble contrast agent has an average particle size of about 10 ⁇ m or less. 15
  • this invention is directed to methods for gynecologic embolotherapy by endovascular embolization with a fluid embolic composition.
  • the methods provide for delivery of a fluid composition to a uterine vascular site which, in situ, forms a coherent solid mass which embolizes the blood vessel.
  • the fluid embolizing composition comprises a biocompatible polymer, a biocompatible solvent and a contrast agent.
  • the contrast agent is a water insoluble contrast agent characterized by having an average particle size of about 10 ⁇ m or less.
  • the fluid embolizing composition comprises a biocompatible prepolymer and a contrast agent.
  • the contrast agent is a water insoluble contrast agent characterized by having an average particle size of about 10 ⁇ m or less. Accordingly, in one aspect the invention provides a method for gynecological embolization comprising: delivering a microcatheter to a uterine artery of a female patient; and delivering a sufficient amount of a fluid embolic material through said microcatheter under conditions wherein the fluid embolic material forms a coherent mass in situ thereby embolizing the blood vessel.
  • the uterine artery is preferably an artery leading to a uterine fibroid.
  • the fluid embolic material is preferably an embolic composition comprising a biocompatible solvent, a biocompatible polymer and a contrast agent.
  • Methods further comprising the step of delivering a detectable agent, such as a contrast agent, through the catheter after it has been inserted into the artery and detecting the agent to confirm that the catheter has the proper placement prior to delivery of embolic material to the vessel are also provided.
  • a detectable agent such as a contrast agent
  • This invention is directed to novel gynecological embolization methods which deliver endovascularly a fluid embolic composition. These methods employ fluid compositions characterized by particle sizes of no more than 100 ⁇ m (preferably less than 10 ⁇ m) which are suited for treating uterine fibroids. Specifically, the fluid compositions used herein provides the benefits heretofore acknowledged while simultaneously providing for a coherent mass in situ thereby overcoming complications heretofore associated with the use of small particles.
  • embolization refers to a process wherein a material is injected into a blood vessel which fills or plugs the blood vessel and/or encourages clot formation so that blood flow through the vessel ceases.
  • Embolization of the blood vessel is, therefore, important in preventing/controlling bleeding due to lesions (e.g. , organ bleeding, gastrointestinal bleeding, vascular bleeding as well as bleeding associated with an aneurysm).
  • embolization can be used to ablate diseased tissue (e.g. , tumors, etc.) by cutting off its blood supply.
  • Embolization may also be used to prevent blood loss during or immediately following surgery.
  • Embolization of tumors may be performed preoperatively to sl-rink tumor size and to aid in visualization of the tumor as well as to prevent blood loss related to surgical procedures.
  • Gynecological embolization refers to embolization used to control acute and chronic genital bleeding in a wide variety of obstetric and gynecological disorders, including uterine fibroids.
  • biocompatible polymer refers to polymers which, in the amounts employed, are. non-toxic, chemically inert, and substantially non- immunogenic when used internally in the patient and which are substantially insoluble in blood.
  • Suitable biocompatible polymers include, by way of example, cellulose acetates 2,6"7 (including cellulose diacetate 5 ), ethylene vinyl alcohol copolymers 4,8 , hydrogels (e.g. , acrylics), polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
  • the biocompatible polymer is also non- inflammatory when employed in situ.
  • biocompatible polymer employed is not critical and is selected relative to the viscosity of the resulting polymer solution, the solubility of the biocompatible polymer in the biocompatible solvent, and the like. Such factors are well within the skill of the art. - 8 -
  • Preferred biocompatible polymers include cellulose diacetate and ethylene vinyl alcohol copolymer.
  • Cellulose diacetate polymers are either commercially available or can be prepared by art recognized procedures.
  • the number average molecular weight, as determined by gel permeation chromatograpuy, of the cellulose diacetate composition is from about 25,000 to about 100,000 more preferably from about 50,000 to about 75,000 and still more preferably from about 58,000 to 64,000.
  • the weight average molecular weight of the cellulose diacetate composition, as determined by gel permeation chromatography, is preferably from about 50,000 to 200,000 and more preferably from about
  • cellulose diacetate polymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight polymers. Accordingly, adjustment of the viscosity of the composition can be readily achieved by mere adjustment of the molecular weight of the polymer composition.
  • Ethylene vinyl alcohol copolymers comprise residues of both ethylene and vinyl alcohol monomers. Small amounts (e.g. , less than 5 mole percent) of additional monomers can be included in the polymer structure or grafted thereon provided such additional monomers do not alter the embolizing properties of the composition.
  • additional monomers include, by way of example only, maleic anhydride, styrene, propylene, acrylic acid, vinyl acetate and the like.
  • Ethylene vinyl alcohol copolymers are either commercially available or can be prepared by art recognized procedures.
  • the ethylene vinyl alcohol copolymer composition is selected such that a solution of 6 weight percent of the ethylene vinyl alcohol copolymer, 35 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20°C.
  • a solution of 6 weight percent of the ethylene vinyl alcohol copolymer, 35 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20°C.
  • copolymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight copolymers. Accordingly, adjustment of the viscosity of the composition as necessary for catheter delivery can be readily achieved by mere adjustment of the molecular weight of the copolymer composition.
  • the ratio of ethylene to vinyl alcohol in the copolymer affects the overall " hydrophobicity/hydrophilicity of the composition which, in turn, affects the relative water solubility/insolubility of the composition as well as the rate of precipitation of the copolymer in an aqueous solution (e.g., blood).
  • the copolymers employed herein comprise a mole percent of ethylene of from about 25 to about 60 and a mole percent of vinyl alcohol of from about 40 to about 75.
  • contrast agent refers to a biocompatible (non-toxic) radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography or fluoroscopy.
  • the contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
  • water insoluble contrast agent refers to a water insoluble (i.e. , has a water solubility of less than 0.01 mg/ml at 20°C), radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography.
  • water insoluble contrast agents include tantalum, tantalum oxide and barium sulfate, which are commercially available in the proper form for in vivo use. Methods for preparing such water insoluble biocompatible contrast agents having an - 10 --
  • water insoluble contrast agents include gold, tungsten and platinum.
  • biocompatible solvent refers to an organic material liquid at least at body temperature of the mammal in which the biocompatible polymer is soluble and, in the amounts used, is substantially non-toxic.
  • suitable biocompatible solvents include, by way of example, dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, ethanol, acetone, and the like.
  • Aqueous mixtures with the biocompatible solvent can also be employed provided that the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood.
  • the biocompatible solvent is dimethylsulfoxide (DMSO).
  • encapsulation as used relative to the contrast agent being encapsulated in the polymer precipitate is not meant to infer any physical entrapment of the contrast agent within the precipitate much as a capsule encapsulates a medicament. Rather, this term is used to mean that an integral coherent precipitate forms which does not separate into individual components.
  • biocompatible prepolymer refers to materials which polymerize in situ to form a polymer and which, in the amounts employed, are non-toxic, chemically inert, and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood.
  • Suitable biocompatible prepolymers include, by way of example, cyanoacrylates 10,11,12 , hydroxyethyl methacrylate, silicon prepolymers, and the like.
  • the prepolymer can either be a monomer or a reactive oligomer 12 .
  • the biocompatible prepolymer is also noninflammatory when employed in situ. - 11 --
  • Endovascular embolization of uterine arteries using embolic compositions comprising small particles, such as PVA particles of about 150-600 ⁇ m, has been disclosed to provide benefits in the endovascular embolization of uterine arteries.
  • these compositions are also linked to greater pelvic pain and potentially lead to endometriosis in the treated patients. 17
  • compositions of this invention are fluid compositions characterized by the fact that these compositions do not contain particles having an average particle size larger than 100 ⁇ m (preferably having an average particle size of no more than 20 ⁇ m and still more preferably no more than 10 ⁇ m) which compositions form a coherent mass in vivo. In some cases such as when the composition employs a water soluble contrast agent, the composition does not need to contain any particles.
  • the fluid compositions employed in the methods of this invention are polymer or prepolymer compositions prepared by conventional methods whereby each of the components is added and the resulting composition mixed together until the overall composition is substantially homogeneous.
  • Fluid polymer compositions preferably comprise a biocompatible polymer, a biocompatible solvent and a contrast agent. Such compositions can be prepared by adding sufficient amounts of the biocompatible polymer to the biocompatible solvent to achieve the effective concentration for the polymer composition.
  • the polymer composition will comprise from about 2.5 to about 8.0 weight percent of the biocompatible polymer composition based on the total weight of the polymer composition and more preferably from about 4 to about 5.2 weight percent. If necessary, gentle heating and stirring can be used to effect dissolution of the biocompatible polymer into the biocompatible solvent, e.g. , 12 hours at 50°C. -- 12 -
  • the composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably about 30 weight percent.
  • the contrast agent may not be soluble in the biocompatible solvent (e.g. , a water insoluble contrast agent)
  • stirring is employed to effect homogeneity of the resulting suspension.
  • the particle size of the water insoluble contrast agent is preferably maintained at about 10 ⁇ m or less and more preferably at from about 1 to about 5 ⁇ m (e.g., an average size of about 2 ⁇ m).
  • the appropriate particle size of the contrast agent is prepared, for example, by fractionation.
  • a water insoluble contrast agent such as tantalum having an average particle size of less than about 20 microns is added to an organic liquid such as ethanol (absolute) preferably in a clean environment. Agitation of the resulting suspension followed by settling for approximately 40 seconds permits the larger particles to settle faster. Removal of the upper portion of the organic liquid followed by separation of the liquid from the particles results in a reduction of the particle size which is confirmed under an optical microscope. The process is optionally repeated until a desired average particle size is reached.
  • the particular order of addition of components to the biocompatible solvent is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition.
  • mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure.
  • the resulting composition is heat - 13 -
  • polymers recited herein is commercially available but can also be prepared by methods well known in the art.
  • polymers are typically prepared by conventional techniques such as radical, thermal, UV, ⁇ irradiation, or electron beam induced polymerization employing, as necessary, a polymerization catalyst or polymerization initiator to provide for the polymer composition.
  • a polymerization catalyst or polymerization initiator to provide for the polymer composition.
  • the specific manner of polymerization is not critical and the polymerization techniques employed do not form a part of this invention.
  • the polymers described herein are preferably not cross-linked.
  • Prepolymer compositions preferably comprise a biocompatible prepolymer and a contrast agent which can be prepared by adding sufficient amounts of the contrast agent to the solution (e.g. , liquid prepolymer) to achieve the effective concentration for the complete composition.
  • the prepolymer composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably about 30 weight percent.
  • stirring is employed to effect homogeneity of the resulting suspension.
  • the particle size of the contrast agent is preferably maintained at about 10 ⁇ m or less and more preferably at from about 1 to about 5 ⁇ m (e.g., an average size of about 2 ⁇ m).
  • the use of a biocompatible solvent is not absolutely necessary but may be preferred to provide for an appropriate - 14 --
  • the biocompatible solvent will comprise from about 30 to about 90 weight percent of the biocompatible prepolymer composition based on the total weight of the prepolymer composition and more preferably from about 60 to about 80 weight percent.
  • the prepolymeric composition typically comprises from about 10 to about 50 weight percent of the prepolymer based on the total weight of the composition.
  • the prepolymer is a cyanoacrylate ester which is preferably employed in the absence of a biocompatible solvent.
  • the cyanoacrylate composition is selected to have a viscosity of from about 5 to about 20 centipoise at 20°C.
  • the particular order of addition of components is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition.
  • mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure.
  • the resulting composition is sterilized and then stored preferably in sealed amber bottles or vials until needed.
  • compositions described above can then be employed in methods for the catheter assisted embolization of uterine arteries.
  • a sufficient amount of this composition is introduced into the selected artery via a catheter delivery means preferably under fluoroscopy so that upon precipitation of the polymer or polymerization of the prepolymer, the blood vessel is embolized.
  • the particular amount of embolizing composition employed is dictated by the total volume of the vasculature to be embolized, the concentration of polymer/prepolymer in the composition, -- 15 --
  • One particularly preferred method for catheter delivering the embolizing compositions of this invention to the selected vascular site is via a small diameter medical catheter.
  • the particular catheter employed is not critical provided that polymeric catheter components are compatible with the embolizing composition (I.e. , the catheter components will not readily degrade in the embolizing composition).
  • polyethylene in the catheter components because of its inertness in the presence of the embolizing composition described herein.
  • Other materials compatible with the embolizing compositions can be readily determined by the skilled artisan and include, for example, other polyolefins, fluoropolymers (e.g. , TeflonTM), silicone, etc.
  • the biocompatible solvent diffuses rapidly into the blood and a solid coherent mass (precipitate) forms in situ which precipitate is the water insoluble polymer with the contrast agent encapsulated therein.
  • a solid coherent mass precipitate
  • precipitate is the water insoluble polymer with the contrast agent encapsulated therein.
  • the methods described herein are useful in gynecological uterine artery embolization to prevent/control bleeding related to gynecological -- 16 -
  • compositions find use in human female and other mammalian female subjects requiring such embolization of blood vessels. Additionally, the methods can be used in the reversible sterilization of mammalian female patients as described in concurrently filed applications by Evans, et ai. iM .
  • Example 1 The purpose of this example is to demonstrate the preparation of a fluid embolic polymer composition useful in the methods of this invention.
  • an EVOH polymer composition was prepared as follows: -- 17 -
  • Component A) was added to Component C) at 50 °C and stirred for 2 hrs. on a hot plate under ah argon blanket.
  • Component B was added to this resulting composition.
  • the average particle size of the contrast agent was prepared by fractionation wherein tantalum, having an average particle size of less than about 20 ⁇ m, was added to ethanol (absolute) in a clean environment. Agitation of the resulting suspension was followed by settling for approximately 40 sec. to permit the larger particles to settle faster. Removal of the upper portion of the ethanol followed by separation of the liquid from the particles results in a reduction of the particle size which is confirmed under a microscope (Nikon AlphaphotTM). The process was repeated, as necessary, until an average 3 ⁇ m particle size was reached.
  • This example is to illustrate a specific protocol for embolizing a mammalian uterine artery via the methods of this invention.
  • This example employed a 60 kg human female (age 45).
  • Example 1 The embolic composition of Example 1 above is shaken for about 4 min. until the contrast agent was fully dispersed.
  • a 150 cm 3 -French polyethylene microcatheter is placed through a femoral artery and directed to a uterine artery leading to a -- 18 -
  • uterine fibroid tumor using a 0.014 in. guidewire while confirming microcatheter placement by injection of water soluble contrast agent (e.g., OmnipaqueTM available from Nycomed, Princeton, New Jersey).
  • water soluble contrast agent e.g., OmnipaqueTM available from Nycomed, Princeton, New Jersey.
  • a syringe containing saline is connected to the luer hub of the microcatheter and the water soluble contrast agent is flushed from the microcatheter hub and body with about 5 cc of saline over an approximately 1 min. period with gentle pulsing at 1 cc increments.
  • the syringe is removed and a cap is secured on the microcatheter luer hub.
  • Sterile DMSO (0.8 cc) is aspirated into a 1 cc syringe.
  • the cap is removed from the microcatheter hub and the syringe fitted thereto.
  • About 0.30 cc of DMSO is injected into the catheter to remove the saline therefrom.
  • the embolic composition While the DMSO is being prepared and injected, the embolic composition is shaken for about 4 min. to fully disperse the water insoluble contrast agent. A 1 cc syringe is then filled with the embolic composition through a 21 gage needle. As soon as the DMSO is injected, the syringe is removed and the balance of the DMSO used for overfilling and washing the luer hub.
  • the syringe containing the embolic composition is immediately connected to the catheter hub, making sure that there is no air in the hub during the connection.
  • the first 0.25 cc is injected over a 1 min. period to displace the DMSO in the microcatheter and dilute the DMSO in the blood.
  • the embolic composition is visible in the distal portion of the microcatheter body.
  • the syringe tip is lowered and the embolic composition then injected as the clinical situation requires.
  • the embolic composition is monitored to ensure that the amount of embolic composition injected corresponded to the volume of the vascular space being filled.
  • the embolic syringe is gently aspirated to separate the catheter tip from the embolic composition mass. After a few seconds, the syringe plunger is released and the microcatheter withdrawn.
  • the embolic composition upon injection into the uterine artery, forms a coherent mass which embolizes the uterine artery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

La présente invention concerne de nouveaux procédés d'embolothérapie gynécologique dans lesquels on effectue une embolisation endovasculaire à l'aide d'une composition embolique liquide qui forme une masse solide cohérente in situ dans le vaisseau sanguin.
EP99908568A 1998-02-27 1999-02-26 Procedes d'embolotherapie gynecologique endovasculaire Withdrawn EP1061988A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3289698A 1998-02-27 1998-02-27
US32896 1998-02-27
PCT/US1999/004398 WO1999043380A1 (fr) 1998-02-27 1999-02-26 Procedes d'embolotherapie gynecologique endovasculaire

Publications (1)

Publication Number Publication Date
EP1061988A1 true EP1061988A1 (fr) 2000-12-27

Family

ID=21867437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99908568A Withdrawn EP1061988A1 (fr) 1998-02-27 1999-02-26 Procedes d'embolotherapie gynecologique endovasculaire

Country Status (5)

Country Link
EP (1) EP1061988A1 (fr)
JP (1) JP2002504406A (fr)
AU (1) AU2796999A (fr)
CA (1) CA2318546A1 (fr)
WO (1) WO1999043380A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355275B1 (en) 2000-06-23 2002-03-12 Carbon Medical Technologies, Inc. Embolization using carbon coated microparticles
US6394965B1 (en) 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US20040202694A1 (en) * 2003-04-11 2004-10-14 Vascular Control Systems, Inc. Embolic occlusion of uterine arteries
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
KR100786796B1 (ko) * 2005-03-25 2007-12-18 주식회사 다음커뮤니케이션 인터넷 광고 과금 방법 및 시스템
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9943380A1 *

Also Published As

Publication number Publication date
JP2002504406A (ja) 2002-02-12
CA2318546A1 (fr) 1999-09-02
AU2796999A (en) 1999-09-15
WO1999043380A1 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
US6059766A (en) Gynecologic embolotherapy methods
US5695480A (en) Embolizing compositions
CA2371321C (fr) Nouvelles compositions d'embolisation de grande viscosite
CA2215356C (fr) Nouvelles compositions d'embolisation
US6335384B1 (en) Methods for embolizing blood vessels
EP1185223A1 (fr) Methodes d'administration in vivo de compositions d'embolisation de grande viscosite dispersees de maniere uniforme
WO1997045131A1 (fr) Compositions a utiliser pour l'embolisation de vaisseaux sanguins
EP1061988A1 (fr) Procedes d'embolotherapie gynecologique endovasculaire
JP5183157B2 (ja) 新規な塞栓形成組成物
HK1124261A (en) Novel high viscosity embolizing compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000915;LT PAYMENT 20000915;LV PAYMENT 20000915;MK PAYMENT 20000915;RO PAYMENT 20000915;SI PAYMENT 20000915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060901